In this exclusive foreword, authors discuss the potential reformation of transplantation and regenerative surgeries that could result from the greater implementation of transplant nanomedicine over transplant immunosuppression.
There has been tremendous interest, investment and progress in cancer nanomedicine over the past 2 decades. Nanomedicine approaches have facilitated safer, more effective and accurate tumor targeting at very low doses of drugs, prolonged half-life/activity and opened possibilities for combining diagnosis and therapy in one agent.
Such ‘theranostic’ nanomedicine could help personalize chemotherapeutic delivery, monitor as well as optimize treatment adequacy or efficacy, and minimize toxicity to improve cancer survivability. In contrast to cancer nanomedicine, the field of transplant nanomedicine is still in its infancy. A PubMed search of the keywords ‘nanomedicine in cancer’ for studies over the past decade results in around 10,000 hits (including many clinical trials) while the keywords ‘nanomedicine in transplantation’ over the same period results in around 800 hits (mostly reviews and no clinical trials). Testament to this is the fact that transplant nanomedicine continues to feature poorly in the scientific agendas of the largest national and international transplant congresses.
In this foreword, Jelena Janjic (Duquesne University; PA, USA) and Vijay Gorantla (Wake Forest University Health Sciences; NC, USA) discuss how transplant nanomedicine may be able to help us accomplish what transplant immunosuppression has failed: namely precisely targeted and personalized treatment with minimal or no collateral systemic side effects.